Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.

By S. Ng, H. Shi, N. Hamidi, F. Underwood, Whitney Tang, E. Benchimol, R. Panaccione, Subrata Ghosh, Justin C.Y. Wu, F. Chan and 2 more. The Lancet, 2017

4,917 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/d0b692c7f2985cc39fa1513906482dc58f885b3c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. F. Powrie
2. M. Pohin
3. M. Friedrich

In Genetics

1. F. Powrie
2. M. Pohin
3. Q. Guan
4. M. Friedrich

Citations in the corpus

• Negative Effects of a High-Fat Diet on Intestinal Permeability: A Review. (2019, background): “For example, celiac disease, IBD, and even colorectal cancer tend to localize to Westernized countries, such as the United States, Canada, and Europe, where a diet high in fats and refined carbohydrates, and low in fiber, predominates (2).”
• A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease (2019, background): “The highest prevalence of IBD was reported in Europe (ulcerative colitis 505 per 100,000 persons in the southeast of Norway; Crohn’s disease 322 per 100,000 persons in Hesse, Germany) and North America (ulcerative colitis 286.3 per 100,000 persons in Olmsted County, USA; Crohn’s disease 318.5 per 10”
• Cytokine Networks in the Pathophysiology of Inflammatory Bowel Disease. (2019, background): “Inflammatory bowel disease (IBD) represents a major healthcare burden of significant global morbidity, with highest prevalence in Europe and North America and rising incidence in Asia (Ng et al., 2018).”
• Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome (2019, background): “The highest incidence rate has been recorded in developed countries, such as North America, Europe, Australia, and New Zealand [6], while recently, IBD has been gradually becoming more common in developing areas such as Asia and South America, and in developing countries such as including Brazil, So”
• The four epidemiological stages in the global evolution of inflammatory bowel disease (2020, neutral): “systematic review by Ng et al.(4)) for Crohn’s”
• Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry (2020, neutral): “Overall 525 363 (69) 161 (31) 24 (5) 21 (4) 16 (3) 37 (7) Age, y 0–9 3 3 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 10–19 26 23 (88) 3 (12) 0 (0) 0 (0) 0 (0) 0 (0) 20–29 116 93 (80) 23 (20) 2 (2) 1 (1) 0 (0) 2 (2) 30–39 108 87 (81) 20 (19) 4 (4) 2 (2) 1 (1) 4 (4) 40–49 95 64 (67) 31 (33) 4 (4) 3 (3) 2 (2) ”